Buy Full Version
"Sleep Aids Market"

Let us help you !

Invalid Email.

Please Select Country.

Invalid contact no.

Special Symbols Not Allowed.

Invalid Security Code.

Thank You For Your Interest.

We've Successfully Got Your Message,

Our Executive will get back to you Shortly.

Sleep Aids Market by Product (Mattress & Pillows, Sleep Laboratories, Medications, and Sleep Apnea Devices) and Sleep Disorder (Insomnia, Sleep Apnea, Restless Leg Syndrome, Narcolepsy, Sleep Walking, and Other Sleep Disorders) - Global Opportunity Analysis and Industry Forecast, 2017-2023
Update Available On-Demand

Healthcare	LI_171533	Pages: 120	Apr 2017 \| 13422 Views
Author(s) : Onkar Sumant and Tenzin Kunsel	Tables: 55	Charts: 58	Formats*:

Sleep Aids Market Overview:

Global Sleep Aids Market size was valued at $49,543 million in 2016, and is estimated to reach $79,851 million by 2023, registering a CAGR of 7.0% from 2017 to 2023. Sleep is a biological requirement that maintain metabolic homeostasis, influences memory and other cognitive function, and regulates immune function. Sleep aids are drugs and medical devices used to diagnose and treat various sleep disorders, such as sleep apnea and insomnia. Lack of quality sleep leads to sleep disorders, which are caused due to medical issues, physical disturbances, environmental problems, and psychiatric disorders. These sleep disorders are expected to adversely affect the human health and lead to number of chronic diseases, such as high blood pressure, diabetes, arthritis, and stroke. Thus, it is important to treat and diagnose these disorders at an early stage. In addition, rising innovations in sleep aid devices, developing drugs for inappropriate sleep and rising utilization of compact sleep apnea devices is relied upon to add to the development of the global sleep aids market.

The global Sleep Aids Market is segmented based on product, sleep disorder, and geography. Based on product, it is classified into mattress & pillows, sleep laboratories, medications, and sleep apnea devices. The medication segment is further divided into prescription-based drugs, over-the-counter (OTC) drugs, and herbal drugs. Based on sleep disorder, it is categorized into insomnia, sleep apnea, restless leg syndrome, narcolepsy, sleep walking, and other sleep disorders. Geographically, it is analyzed across North America, Europe, Asia-Pacific, and LAMEA.

Global Sleep Aids Market Segmentation

Get more information on this report : Request Sample Pages

Drivers, Restrains, and Opportunities

The impact of the driving factors is expected to surpass the effect of restraints. Moreover, the increase in awareness about sleep disorders and technological advancements are expected to provide new market opportunities to sleep aids manufacturers in the near future.

Drivers, Restrains, and Opportunities

Get more information on this report : Request Sample Pages

Global Sleep Aids Market Key Geographical Segment

North America accounted for the highest sleep aids market share in 2016, and is expected to maintain its dominance throughout the forecast period.

Global Sleep Aids Market, By Geography, 2016 (%)

Get more information on this report : Request Sample Pages

The key players operating in the global sleep aids market include

Koninklijke Philips N.V.
Merck & Co.
Sanofi
eVilbiss Healthcare LLC.
Pfizer Inc.
SleepMed Inc.
Cadwell Laboratories Inc.
Compumedics Limited
Natus Medical Incorporated, and
GlaxoSmithKline plc

The other significant players in the value chain include Teva Pharmaceutical Industries Ltd., Takeda Pharmaceutical Company Limited, CareFusion Corporation, Tempur-Pedic Management Inc., Serta International, and Drive Medical Ltd.

Key Benefits for Stakeholders:

The report provides an in depth analysis of the current sleep aids market trends
The major countries in North America have been mapped according to their individual revenue contribution to the regional market
Porter’s five forces analysis helps to analyze the potential of the buyers & suppliers and the competitive scenario of the industry for strategy building
The sleep aids market size for product is mentioned in the report in terms of revenue and volume
It outlines the current trends and future scenario of the market from 2016 to 2023 to understand the prevailing opportunities and potential investment pockets
The key drivers, restraints, and opportunities and their detailed impact analyses are elucidated in the study
The profiles of key players along with their key strategic developments are enlisted in the report

Sleep Aids Market Key Segments:

By Product

Mattresses & Pillows
Sleep Laboratories
Medications
- Prescription-based Drugs
- OTC drugs
- Herbal drugs
Sleep Apnea Devices

By Sleep Disorder

Insomnia
Sleep Apnea
Restless Legs Syndrome
Narcolepsy
Sleep Walking
Other Sleep Disorders

By Geography

North America
- U.S.
- Canada
- Mexico
Europe
- Germany
- UK
- France
- Spain
- Rest of Europe
Asia-Pacific
- Japan
- China
- Australia
- India
- Rest of Asia-Pacific
LAMEA
- Brazil
- Turkey
- Republic of South Africa
- Saudi Arabia
- Rest of LAMEA

CHAPTER 1 INTRODUCTION

1.1. REPORT DESCRIPTION
1.2. KEY BENEFITS
1.3. KEY MARKET SEGMENTS
1.4. RESEARCH METHODOLOGY

1.4.1. Secondary research
1.4.2. Primary research
1.4.3. Analyst tools and models

CHAPTER 2 EXECUTIVE SUMMARY

2.1. CXO PERSPECTIVE

CHAPTER 3 MARKET OVERVIEW

3.1. MARKET DEFINITION AND SCOPE
3.2. KEY BENEFITS

3.2.1. Top investment pockets
3.2.2. Top winning strategies

3.3. PATENT ANALYSIS

3.3.1. Patent analysis by year
3.3.2. Patent analysis by region
3.3.3. Patent analysis by sleep disorder

3.4. GOVERNMENT REGULATIONS

3.4.1. U.S. FDA
3.4.2. Europe CE Mark
3.4.3. Ministry of Health, Labor, and Welfare (MHLW)

3.5. TOP PLAYERS POSITIONING, 2016
3.6. MARKET DYNAMICS

3.6.1. Drivers

3.6.1.1. Modern lifestyle increases the risk of sleep disorders
3.6.1.2. Stressful Work Condition and Working in Shifts
3.6.1.3. Rise in geriatric and obese population

3.6.2. Restraints

3.6.2.1. Adverse effects of sleep aid medication
3.6.2.2. Patent expiration

3.6.3. Opportunities

3.6.3.1. Technological Advancements Leading to Better Adoption
3.6.3.2. Untapped Markets in Developing Economies

CHAPTER 4 GLOBAL SLEEP AIDS MARKET, BY PRODUCT TYPE

4.1. OVERVIEW

4.1.1. Market size and forecast

4.2. MATTRESSES AND PILLOWS

4.2.1. Key market trends
4.2.2. Key growth factors and opportunities
4.2.3. Market size and forecast

4.3. SLEEP LABORATORIES

4.3.1. Key market trends
4.3.2. Key growth factors and opportunities
4.3.3. Market size and forecast

4.4. MEDICATIONS

4.4.1. Key market trends
4.4.2. Key growth factors and opportunities
4.4.3. Market size and forecast
4.4.4. Prescription-based drugs
4.4.5. OTC drugs

4.5. SLEEP APNEA DEVICES

4.5.1. Key market trends
4.5.2. Key growth factors and opportunities
4.5.3. Market size and forecast

CHAPTER 5 SLEEP AIDS MARKET, BY SLEEP DISORDER

5.1. OVERVIEW

5.1.1. Market size and forecast

5.2. INSOMNIA

5.2.1. Market size and forecast

5.3. SLEEP APNEA

5.3.1. Market size and forecast

5.4. RESTLESS LEGS SYNDROME

5.4.1. Market size and forecast

5.5. NARCOLEPSY

5.5.1. Market size and forecast

5.6. SLEEPWALKING

5.6.1. Market size and forecast

5.7. OTHERS

5.7.1. Market size and forecast

CHAPTER 6 SLEEP AIDS MARKET, BY GEOGRAPHY

6.1. OVERVIEW

6.1.1. Market size and forecast

6.2. NORTH AMERICA

6.2.1. Key market trends
6.2.2. Key growth factors and opportunities
6.2.3. Market size and forecast

6.2.3.1. U.S. market size and forecast
6.2.3.2. Canada market size and forecast
6.2.3.3. Mexico market size and forecast

6.3. EUROPE

6.3.1. Key market trends
6.3.2. Key growth factors and opportunities
6.3.3. Market size and forecast

6.3.3.1. Germany market size and forecast
6.3.3.2. France market size and forecast
6.3.3.3. UK market size and forecast
6.3.3.4. Italy market size and forecast
6.3.3.5. Rest of Europe market size and forecast

6.4. ASIA-PACIFIC

6.4.1. Key market trends
6.4.2. Key growth factors and opportunities
6.4.3. Market size and forecast

6.4.3.1. Japan market size and forecast
6.4.3.2. China market size and forecast
6.4.3.3. Australia market size and forecast
6.4.3.4. India market size and forecast
6.4.3.5. Rest of Asia-Pacific market size and forecast

6.5. LAMEA

6.5.1. Key market trends
6.5.2. Key growth factors and opportunities
6.5.3. Market size and forecast

6.5.3.1. Brazil market size and forecast
6.5.3.2. Turkey market size and forecast
6.5.3.3. Saudi Arabia market size and forecast
6.5.3.4. South Africa market size and forecast
6.5.3.5. Rest of LAMEA market size and forecast

CHAPTER 7 COMPANY PROFILES

7.1. CADWELL INDUSTRIES INC.

7.1.1. Company overview
7.1.2. Company snapshot
7.1.3. Operating business segments
7.1.4. Product portfolio
7.1.5. Business performance
7.1.6. Key strategic moves and developments

7.2. COMPUMEDICS LIMITED

7.2.1. Company overview
7.2.2. Company snapshot
7.2.3. Operating business segments
7.2.4. Product portfolio
7.2.5. Business performance
7.2.6. Key strategic moves and developments

7.3. DRIVE DEVILBISS HEALTHCARE

7.3.1. Company overview
7.3.2. Company snapshot
7.3.3. Operating business segments
7.3.4. Product portfolio
7.3.5. Business performance
7.3.6. Key strategic moves and developments

7.4. GLAXOSMITHKLINE PLC

7.4.1. Company overview
7.4.2. Company snapshot
7.4.3. Operating business segments
7.4.4. Product portfolio
7.4.5. Business performance
7.4.6. Key strategic moves and developments

7.5. MERCK & CO., INC.

7.5.1. Company overview
7.5.2. Company snapshot
7.5.3. Operating business segments
7.5.4. Product portfolio
7.5.5. Business performance
7.5.6. Key strategic moves and developments

7.6. NATUS MEDICAL INCORPORATED

7.6.1. Company overview
7.6.2. Company snapshot
7.6.3. Operating business segments
7.5.4. Product portfolio
7.5.5. Business performance
7.6.6. Key strategic moves and developments

7.7. PFIZER INC.

7.7.1. Company overview
7.7.2. Company snapshot
7.7.3. Operating business segments
7.7.4. Product portfolio
7.7.5. Business performance
7.7.6. Key strategic moves and developments

7.8. KONINKLIJKE PHILIPS N.V.

7.8.1. Company overview
7.8.2. Company snapshot
7.8.3. Operating business segments
7.8.4. Product portfolio
7.8.5. Business performance
7.8.6. Key strategic moves and developments

7.9. SANOFI

7.9.1. Company overview
7.9.2. Company snapshot
7.9.3. Product portfolio
7.9.4. Business performance
7.9.5. Key strategic moves and developments

7.10. SLEEPMED INC.

7.10.1. Company overview
7.10.2. Company snapshot
7.10.3. Operating business segments
7.10.4. Product portfolio
7.10.5. Business performance
7.10.6. Key strategic moves and developments

LIST OF TABLES

TABLE 1. GLOBAL SLEEP AIDS MARKET, BY PRODUCT TYPE, 2016-2023 ($MILLION)
TABLE 2. SLEEP AIDS MATTRESS AND PILLOWS MARKET, BY GEOGRAPHY, 2016-2023 ($MILLION)
TABLE 3. SLEEP AIDS SLEEP LABORATORIES MARKET, BY GEOGRAPHY, 2016-2023 ($MILLION)
TABLE 4. SLEEP AIDS MEDICATIONS MARKET, BY TYPE, 2016-2023 ($MILLION)
TABLE 5. SLEEP AIDS PRESCRIPTION-BASED DRUGS MARKET, BY GEOGRAPHY, 2016-2023 ($MILLION)
TABLE 6. SLEEP AIDS OTC DRUGS MARKET, BY GEOGRAPHY, 2016-2023 ($MILLION)
TABLE 7. GLOBAL SLEEP AIDS MARKET, BY SLEEP DISORDER, 2016-2023 ($MILLION)
TABLE 8. INSOMNIA SLEEP AIDS MARKET, BY GEOGRAPHY, 2016-2023 ($MILLION)
TABLE 9. SLEEP APNEA SLEEP AIDS MARKET, BY GEOGRAPHY, 2016-2023 ($MILLION)
TABLE 10. RESTLESS LEGS SYNDROME SLEEP AIDS MARKET, BY GEOGRAPHY, 2016-2023 ($MILLION)
TABLE 11. NARCOLEPSY SLEEP AIDS MARKET, BY GEOGRAPHY, 2016-2023 ($MILLION)
TABLE 12. SLEEPWALKING MEDICAL SLEEP AIDS MARKET, BY GEOGRAPHY, 2016-2023 ($MILLION)
TABLE 13. OTHER SLEEP DISORDERS SLEEP AIDS MARKET, BY GEOGRAPHY, 2016-2023 ($MILLION)
TABLE 14. NORTH AMERICA SLEEP AIDS MARKET, BY PRODUCT TYPE, 2016-2023 ($MILLION)
TABLE 15. NORTH AMERICA SLEEP AIDS MARKET, BY MEDICATION, 2016-2023 ($MILLION)
TABLE 16. NORTH AMERICA SLEEP AIDS MARKET, BY SLEEP DISORDER, 2016-2023 ($MILLION)
TABLE 17. NORTH AMERICA SLEEP AIDS MARKET, BY COUNTRY, 2016-2023 ($MILLION)
TABLE 18. EUROPE SLEEP AIDS MARKET, BY PRODUCT TYPE, 2016-2023 ($MILLION)
TABLE 19. EUROPE SLEEP AIDS MARKET, BY MEDICATION, 2016-2023 ($MILLION)
TABLE 20. EUROPE SLEEP AIDS MARKET, BY SLEEP DISORDER, 2016-2023 ($MILLION)
TABLE 21. EUROPE SLEEP AIDS MARKET, BY COUNTRY, 2016-2023 ($MILLION)
TABLE 22. ASIA-PACIFIC SLEEP AIDS MARKET, BY PRODUCT TYPE, 2016-2023 ($MILLION)
TABLE 23. ASIA-PACIFIC SLEEP AIDS MARKET, BY MEDICATION, 2016-2023 ($MILLION)
TABLE 24. ASIA-PACIFIC SLEEP AIDS MARKET, BY SLEEP DISORDER, 2016-2023 ($MILLION)
TABLE 25. ASIA-PACIFIC SLEEP AIDS MARKET, BY COUNTRY, 2016-2023 ($MILLION)
TABLE 26. LAMEA SLEEP AIDS MARKET, BY PRODUCT TYPE, 2016-2023 ($MILLION)
TABLE 27. LAMEA SLEEP AIDS MARKET, BY MEDICATION, 2016-2023 ($MILLION)
TABLE 28. LAMEA SLEEP AIDS MARKET, BY SLEEP DISORDER, 2016-2023 ($MILLION)
TABLE 29. LAMEA SLEEP AIDS MARKET, BY COUNTRY, 2016-2023 ($MILLION)
TABLE 30. CADWELL: COMPANY SNAPSHOT
TABLE 31. CADWELL: OPERATING SEGMENTS
TABLE 32. CADWELL: PRODUCT PORTFOLIO
TABLE 33. COMPUMEDICS: COMPANY SNAPSHOT
TABLE 34. COMPUMEDICS: OPERATING SEGMENTS
TABLE 35. DRIVE DEVILBISS HEALTHCARE: COMPANY SNAPSHOT
TABLE 36. DRIVE DEVILBISS HEALTHCARE: OPERATING SEGMENTS
TABLE 37. DRIVE DEVILBISS HEALTHCARE: PRODUCT PORTFOLIO
TABLE 38. GSK: COMPANY SNAPSHOT
TABLE 39. GSK: OPERATING SEGMENTS
TABLE 40. MERCK: COMPANY SNAPSHOT
TABLE 41. MERCK: OPERATING SEGMENTS
TABLE 42. NATUS: PRODUCT PORTFOLIO
TABLE 43. NATUS: COMPANY SNAPSHOT
TABLE 44. NATUS: OPERATING SEGMENTS
TABLE 45. PFIZER: COMPANY SNAPSHOT
TABLE 46. PFIZER: OPERATING SEGMENTS
TABLE 47. PFIZER: PRODUCT PORTFOLIO
TABLE 48. PHILIPS: COMPANY SNAPSHOT
TABLE 49. PHILIPS: OPERATING SEGMENTS
TABLE 50. PHILIPS: PRODUCT PORTFOLIO
TABLE 51. SANOFI: COMPANY SNAPSHOT
TABLE 52. SANOFI: PRODUCT PORTFOLIO
TABLE 53. SLEEPMED: COMPANY SNAPSHOT
TABLE 54. SLEEPMED: OPERATING SEGMENTS
TABLE 55. SLEEPMED: PRODUCT PORTFOLIO

LIST OF FIGURES

FIGURE 1. MARKET SEGMENTATION
FIGURE 2. TOP INVESTMENT POCKETS IN GLOBAL SLEEP AIDS MARKET
FIGURE 3. TOP WINNING STRATEGIES: PERCENTAGE DISTRIBUTION (2015-2017) (%)
FIGURE 4. TOP WINNING STRATEGIES IN SLEEP AIDS MARKET (2015-2017)
FIGURE 5. TOP WINNING STRATEGIES: TYPE AND NATURE
FIGURE 11. TOP PLAYER POSITIONING: GLOBAL SLEEP AIDS MARKET, 2016
FIGURE 12. GLOBAL SLEEP AIDS MARKET: RESTRAINTS AND DRIVERS
FIGURE 13. GLOBAL SLEEP AIDS MARKET SEGMENTATION, BY APPLICATION
FIGURE 14. U.S. SLEEP AIDS MARKET, 2016-2023 ($MILLION)
FIGURE 15. CANADA SLEEP AIDS MARKET, 2016-2023 ($MILLION)
FIGURE 16. MEXICO SLEEP AIDS MARKET, 2016-2023 ($MILLION)
FIGURE 17. GERMANY SLEEP AIDS MARKET, 2016-2023 ($MILLION)
FIGURE 18. FRANCE SLEEP AIDS MARKET, 2016-2023 ($MILLION)
FIGURE 19. UK SLEEP AIDS MARKET, 2016-2023 ($MILLION)
FIGURE 20. ITALY SLEEP AIDS MARKET, 2016-2023 ($MILLION)
FIGURE 21. REST OF EUROPE SLEEP AIDS MARKET, 2016-2023 ($MILLION)
FIGURE 22. JAPAN SLEEP AIDS MARKET, 2016-2023 ($MILLION)
FIGURE 23. CHINA SLEEP AIDS MARKET, 2016-2023 ($MILLION)
FIGURE 24. AUSTRALIA SLEEP AIDS MARKET, 2016-2023 ($MILLION)
FIGURE 25. INDIA SLEEP AIDS MARKET, 2016-2023 ($MILLION)
FIGURE 26. REST OF ASIA-PACIFIC SLEEP AIDS MARKET, 2016-2023 ($MILLION)
FIGURE 27. BRAZIL SLEEP AIDS MARKET, 2016-2023 ($MILLION)
FIGURE 28. TURKEY SLEEP AIDS MARKET, 2016-2023 ($MILLION)
FIGURE 29. SAUDI ARABIA SLEEP AIDS MARKET, 2016-2023 ($MILLION)
FIGURE 30. SOUTH AFRICA SLEEP AIDS MARKET, 2016-2023 ($MILLION)
FIGURE 31. REST OF LAMEA SLEEP AIDS MARKET, 2016-2023 ($MILLION)
FIGURE 32. CADWELL: REVENUE, 2016-2016 ($MILLION)
FIGURE 33. CADWELL: REVENUE SHARE BY GEOGRAPHY, 2016 (%)
FIGURE 34. COMPUMEDICS: REVENUE, 2016-2016 ($MILLION)
FIGURE 35. COMPUMEDICS: REVENUE BY SEGMENT, 2016 (%)
FIGURE 36. DRIVE DEVILBISS HEALTHCARE: REVENUE, 2016-2016 ($MILLION)
FIGURE 37. DRIVE DEVILBISS HEALTHCARE: REVENUE SHARE BY PRODUCT TYPE, 2016 (%)
FIGURE 38. DRIVE DEVILBISS HEALTHCARE: REVENUE SHARE BY GEOGRAPHY, 2016 (%)
FIGURE 39. GSK: REVENUE, 2016-2016 ($MILLION)
FIGURE 40. GSK: REVENUE SHARE BY SEGMENT, 2016 (%)
FIGURE 41. GSK: REVENUE SHARE BY GEOGRAPHY, 2016 (%)
FIGURE 42. MERCK: REVENUE, 2016-2016 ($MILLION)
FIGURE 43. MERCK: REVENUE BY SEGMENT, 2016 (%)
FIGURE 44. MERCK: REVENUE BY GEOGRAPHY, 2016 (%)
FIGURE 45. NATUS: REVENUE, 2016-2016 ($MILLION)
FIGURE 46. NATUS: REVENUE SHARE BY GEOGRAPHY, 2015 (%)
FIGURE 47. PFIZER: REVENUE, 2016-2016 ($MILLION)
FIGURE 48. PFIZER: REVENUE SHARE BY SEGMENT, 2016 (%)
FIGURE 49. PFIZER: REVENUE SHARE BY GEOGRAPHY, 2016 (%)
FIGURE 50. PHILIPS: REVENUE, 2016-2016 ($MILLION)
FIGURE 51. PHILIPS: REVENUE SHARE BY SEGMENT, 2016 (%)
FIGURE 52. PHILIPS: REVENUE SHARE BY GEOGRAPHY, 2016 (%)
FIGURE 53. SANOFI: REVENUE, 2016-2016 ($MILLION)
FIGURE 54. SANOFI: REVENUE SHARE BY SEGMENT, 2016 (%)
FIGURE 55. SANOFI: REVENUE SHARE BY GEOGRAPHY, 2016 (%)
FIGURE 56. SLEEPMED: REVENUE, 2016-2016 ($MILLION)
FIGURE 57. SLEEPMED: REVENUE SHARE BY SEGMENT, 2016 (%)
FIGURE 58. SLEEPMED: REVENUE SHARE BY GEOGRAPHY, 2016 (%)

Sleep aid products are gaining popularity due to rise in the awareness about the sleep disorders and the advancement in sleep aids technology. These products in the form of drugs and devices are used to improve the quality of sleep of the patient. Moreover, these helps in the diagnosis and treatment of sleep disorders, such as insomnia, narcolepsy, and sleep walking.

Risk of sleep disorder increases with age and obesity, thus the increase in geriatric and obese population supplements the market growth. Moreover, rise in the initiative by healthcare organization to increase awareness about the adverse effects of sleep disorder on human health, change in lifestyle, and inconsistent sleep patterns are expected to boost the market growth. However, the side effects of using sleep medication and patent expiration are expected to hamper the market growth.

The sleep laboratories segment is expected to grow at a highest rate and provide lucrative opportunities for the market players. These are used for the diagnosis and treatment of sleep disorders, and the presence of a large undiagnosed patients suffering from sleep disorder is anticipated to boost growth of this segment.

The employment of sleep aids is highest in North America, owing to the increase in adoption of these products, high awareness regarding the benefits of quality sleep among the consumers, and increase in disposable income. Although the use of sleep aids in Asia-Pacific and LAMEA region is low, the adoption rate is expected to increase, owing to rise in disposable income, presence of large geriatric and obese population.